Albert David
707.15
+9.85(+1.41%)
Market Cap₹403.58 Cr
PE Ratio41.57
IndustryHealthcare
Company Performance:
1D+1.41%
1M+9.66%
6M-11.73%
1Y-19.40%
5Y+57.44%
View Company Insightsright
More news about Albert David
12Nov 25
Albert David Limited Reports Q2 FY26 Results: Revenue Declines, Net Loss Narrows
Albert David Limited, a pharmaceutical manufacturer, released its Q2 FY26 results. Revenue decreased to Rs. 5,857.00 lakhs from Rs. 7,056.64 lakhs in Q1. Net loss reduced to Rs. 540.04 lakhs from Rs. 779.76 lakhs. H1 FY26 revenue totaled Rs. 13,779.18 lakhs with a net loss of Rs. 526.71 lakhs. The company paid a Rs. 5.00 per share dividend. Total assets increased to Rs. 53,294.06 lakhs, and total equity rose slightly to Rs. 39,389.66 lakhs. The company faced operational cash flow challenges but saw positive financing cash flow.
 no imag found
17Sept 25
Albert David Shareholders Approve Dr. Rajiv Anant Desai's Appointment as Independent Director
Albert David, a pharmaceutical company, has appointed Dr. Rajiv Anant Desai as an Independent Director for a five-year term from August 2, 2025, to August 1, 2030. The appointment was approved through a postal ballot with 99.99% of votes in favor. Dr. Desai, with over 38 years of experience in the pharmaceutical industry, holds a Ph.D. in Pharmaceutical Chemistry and an MBA. He previously served as Executive Vice President at Lupin Limited and currently works as a Senior Technical Advisor with the Indian Pharmaceutical Alliance.
 no imag found
04Aug 25
Albert David Limited Reports Mixed Q1 FY2026 Results with Decline in Revenue and Profit
Albert David, a pharmaceutical company, released Q1 FY2026 results showing a 21% year-on-year revenue decline to Rs. 7,056.64 lakhs. Net profit fell 58% to Rs. 793.76 lakhs. EPS decreased to Rs. 13.91 from Rs. 33.02 in Q1 FY2025. The company's equity share capital remained unchanged at Rs. 570.72 lakhs. The results were approved by the board on August 2, 2025, after a limited review by statutory auditors.
 no imag found
02Aug 25
Albert David Limited Appoints Pharma Veteran as New Independent Director, Approves Q1 Results
Albert David Limited's board approved Q1 financial results for the quarter ended June 30, 2025. The company appointed Dr. Rajiv Anant Desai as an Additional Non-Executive Independent Director, effective August 2, 2025, subject to shareholder approval via postal ballot. Dr. Desai, 63, brings 38 years of pharmaceutical industry experience, including roles at Lupin Limited and Indian Pharmaceutical Alliance. His appointment is for a five-year term.
 no imag found
02Aug 25
Albert David Reports 59% Decline in Q1 Net Profit, Appoints New Independent Director
Albert David Limited's Q1 net profit declined by 59.30% to ₹77.50 million from ₹190.40 million year-over-year. The Board approved Q1 financial results and appointed Dr. Rajiv Anant Desai as Additional Non-Executive Independent Director for five years, effective August 2, subject to shareholder approval. Dr. Desai brings 38 years of pharmaceutical industry experience, including roles at Indian Pharmaceutical Alliance and Lupin Limited.
 no imag found
13May 25
Albert David Ltd Reports Q4 FY23 Results: EBITDA Loss Widens, Revenue Declines; Recommends Dividend
Albert David Ltd's Q4 FY23 results show a 15.94% YoY revenue decline to ₹749.00 crore. EBITDA swung to a loss of ₹48.00 crore from a profit of ₹96.00 crore in Q4 FY22. Net loss improved by 20.16% YoY to ₹103.00 crore. The company recommended a dividend of ₹5 per equity share despite financial challenges.
 no imag found
Albert David
707.15
+9.85
(+1.41%)
1 Year Returns:-19.40%
Industry Peers
Sun Pharmaceutical
1,735.80
(+7.12%)
Divis Laboratories
6,457.50
(+1.51%)
Torrent Pharmaceuticals
4,225.00
(+2.62%)
Dr Reddys Laboratories
1,335.00
(+1.36%)
Cipla
1,314.20
(+1.48%)
Lupin
2,319.60
(+1.02%)
Zydus Life Science
948.60
(+2.29%)
Mankind Pharma
2,301.10
(+1.49%)
Aurobindo Pharma
1,422.80
(+0.64%)
Glenmark Pharmaceuticals
2,296.50
(-0.13%)